Sintilimab combined with lenvatinib versus hepatic artery infusion chemotherapy (HAIC) for neoadjuvant treatment of resectable primary hepatocellular carcinoma with high risk of recurrence: A prospective, two-arm, randomized, phase II clinical study.

Authors

Feng Fang (ORCID: https://orcid.org/0000-0002-9568-8332)
Ping Chen (ORCID: https://orcid.org/0000-0002-8504-5552)
Han Mu
Yunlong Cui
Yu Ge (ORCID: https://orcid.org/0000-0001-7153-5035)
Chen Liu (ORCID: https://orcid.org/0009-0003-0430-6146)
Wei Zhang (ORCID: https://orcid.org/0000-0003-0875-263X)
Qiang Wu (ORCID: https://orcid.org/0000-0003-4607-2934)
Xu Bao (ORCID: https://orcid.org/0000-0003-3350-2456)
Guangtao Li (ORCID: https://orcid.org/0000-0002-8128-2032)
Tianqiang Song (ORCID: https://orcid.org/0000-0001-8456-9015)

Institutions

Tianjin Medical University Cancer Institute and Hospital (CN)

Publication Details

Journal: Journal of Clinical Oncology
Published: 2025-05-28
DOI: https://doi.org/10.1200/jco.2025.43.16_suppl.e16301
Primary Topic: Hepatocellular Carcinoma Treatment and Prognosis
Type: article
Field-Weighted Citation Impact: 0.00

Controls

|||

ALL TIME

JAN

FEB

MAR

APR

MAY

JUN

JUL

AUG

SEP

OCT

article

Sintilimab combined with lenvatinib versus hepatic artery infusion chemotherapy (HAIC) for neoadjuvant treatment of resectable primary hepatocellular carcinoma with high risk of recurrence: A prospective, two-arm, randomized, phase II clinical study.

Feng Fang, Ping Chen, Han Mu, Yunlong Cui et al.

May 28, 2025

Journal of Clinical Oncology

Hepatocellular Carcinoma Treatment and Prognosis

article

Sintilimab combined with lenvatinib versus hepatic artery infusion chemotherapy (HAIC) for neoadjuvant treatment of resectable primary hepatocellular carcinoma with high risk of recurrence: A prospective, two-arm, randomized, phase II clinical study.

Feng Fang, Ping Chen, Han Mu, Yunlong Cui, Yu Ge, Chen Liu, Wei Zhang, Qiang Wu, Xu Bao, Guangtao Li, Tianqiang Song

May 28, 2025article en

Abstract

No abstract available for this paper.

Journal of Clinical OncologyVol. 43(16_suppl)

Tianjin Medical University Cancer Institute and Hospital (CN)

Openalex Percentile: Top 82%

Hepatocellular Carcinoma Treatment and Prognosis

DOI Source OpenAlex

AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.